Clinical Trial Update: Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating dose escalation and safety of duloxetine hydrochloride given once daily for major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Duloxetine hydrochloride (Cymbalta) (duloxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED